$40.70−0.90 (−2.16%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$40.12−0.58 (−1.43%)
After hours: Nov 17, 2026, 7:57 PM ET
Novo Nordisk (NVO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~22.7%/yr (FY21→FY25), net margin 33.1%; free cash flow runs at 73% of net income. Check the accrual gap.
The four lines that matter · FY21–FY25
Revenue ($B)▲20.5%
48.6
FY21→FY25CAGR +22.7%/yr
Net income ($B)▲14.8%
16.1
FY21→FY25CAGR +22.0%/yr
Free cash flow ($B)▼24.4%
11.7
FY21→FY25CAGR +9.2%/yr
Diluted EPS▲15.2%
3.62
buyback-liftedCAGR −23.1%/yr
What the receipts whisper · what a headline number hides
Share count
−100.0%
2280.0tn → 0.0tn diluted shares since FY22. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$9.5B
+44.4% YoY in FY25 · 19.5% of revenue.
Returns vs FCF
71%
$8.4B returned vs $11.7B of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
33¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 83.2% → 81.0%. Net margin 33.1% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 48,564.4 | 48,564.4 | 40,308.0 | 34,466.2 | 25,455.9 | 21,429.4 | ▲20.5% | +22.7% |
Cost of revenue | 9,237.6 | 9,237.6 | 6,179.7 | 5,307.3 | 4,092.4 | 3,600.7 | ▲49.5% | +26.6% |
Gross profit | 39,326.8 | 39,326.8 | 34,128.3 | 29,158.9 | 21,363.5 | 17,828.7 | ▲15.2% | +21.9% |
Research & development | 8,177.1 | 8,177.1 | 6,671.0 | 4,814.4 | 3,459.3 | 2,704.9 | ▲22.6% | +31.9% |
Selling, general & admin | 11,043.2 | 11,043.2 | 9,351.9 | 9,140.8 | 7,291.2 | 6,248.9 | ▲18.1% | +15.3% |
Total operating expenses | 19,267.4 | 19,267.4 | 16,314.9 | 13,937.5 | 10,601.7 | 8,903.3 | ▲18.1% | +21.3% |
Operating incomefeeds ROC rank | 20,059.4 | 20,059.4 | 17,813.5 | 15,221.4 | 10,761.7 | 8,925.5 | ▲12.6% | +22.4% |
Other income, net | 452.9 | 452.9 | −159.3 | 311.6 | −826.7 | 66.4 | — | — |
Pretax income | 20,512.3 | 20,512.3 | 17,654.1 | 15,533.0 | 9,935.0 | 8,991.8 | ▲16.2% | +22.9% |
Income tax | 4,416.4 | 4,416.4 | 3,637.0 | 3,114.9 | 1,947.4 | 1,723.3 | ▲21.4% | +26.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 16,095.9 | 16,095.9 | 14,017.2 | 12,418.1 | 7,987.6 | 7,268.5 | ▲14.8% | +22.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.62 | 3.62 | 3.14 | 2.76 | 1.76 | 10.37 | ▲15.2% | −23.1% |
Diluted shares (tn) | 0.00 | 0.00 | 0.00 | 0.00 | 2,280.00 | 0.00 | ▲0.0% | +17.9% |
| Margins | ||||||||
Gross margin75th pct in Healthcare | 81.0% | 81.0% | 84.7% | 84.6% | 83.9% | 83.2% | ▼3.7pp | −2.2pp |
Operating margin | 41.3% | 41.3% | 44.2% | 44.2% | 42.3% | 41.7% | ▼2.9pp | −0.3pp |
Net margin96th pct in Healthcare | 33.1% | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | ▼1.6pp | −0.8pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Novo Nordisk's revenue last fiscal year?
Novo Nordisk reported revenue of $48.6B in fiscal 2025, up 20.5% from fiscal 2024.
What was Novo Nordisk's net income?
Novo Nordisk reported net income of $16.1B in fiscal 2025, a net margin of 33.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

